Richard Gaster

VenBio is a life sciences investment firm that partners with industry leaders to build medicines and technologies.

Entact Bio is a biotechnology company that is in the preclinical stages of developing medications to improve protein function.

Raised $121,321,700.00 from Surveyor Capital, Arkin Bio Ventures, Janus Henderson Investors, Walter and Eliza Hall Institute of Medical Research, Brandon Capital, Abingworth, Qiming Venture Partners USA, venBio Partners, Logos Capital and 4BIO Capital.

Attralus is a biopharmaceutical company focusing on creating transformative medicines to improve the lives of patients.

Raised $197,000,000.00 from venBio Partners, Sarissa Capital Management, Vivo Capital, Logos Capital, Surveyor Capital, Bristol-Myers Squibb, Alpha Wave Ventures, Sarissa Capital Management, venBio Partners and Logos Capital.

Arrakis Therapeutics is a biopharmaceutical developing drugs for neurological disorders and other diseases.

Raised $113,000,000.00 from WuXi AppTec, venBio Partners, OUP (Osage University Partners), Alexandria Venture Investments, Henri Termeer, Omega Funds, Advent Life Sciences, Nextech Invest, Canaan Partners and Celgene.

ACELYRIN is a biopharma company that identifies, acquires, and accelerates the development and commercialization of life-changing therapies.

Raised $558,000,000.00 from Westlake Village BioPartners, Cowen Healthcare Investments, OrbiMed, Samsara BioCapital, Decheng Capital, Matrix Capital Management, venBio Partners, Marshall Wace, Access Biotechnology and Tybourne Capital Management.

Ventyx is a biopharmaceutical company focused on advancing oral therapies for patients living with autoimmune and inflammatory disorders.

Raised $468,600,000.00 from Sanofi, Redmile Group, Surveyor Capital, Farallon Capital Management, Cormorant Asset Management, EcoR1 Capital, CaaS Capital Management, Acuta Capital Partners, Boxer Capital and Redmile Group.